The anticonvulsants market is set to strengthen its position at a lower CAGR of 2.4% during the forecast period. The market holds the revenue of US$ 25.17 Bn in 2023 while it is likely to cross a value of US$ 31.91 Bn by 2033.
| Attributes | Details |
|---|---|
| Anticonvulsants Market Size (2023E) | US$ 25.17 Billion |
| Anticonvulsants Projected Size (2033F) | US$ 31.91 Billion |
| Value CAGR (2023 to 2033) | 2.4% |
Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures.
Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used in treatment of bipolar disorder and in neuropathic pain management.
Anyone could potentially have a single epileptic seizure at some point in their lives. This is not the same as having epilepsy, which is a tendency to have seizures that start in the brain. Epilepsy can affect people of any age group. Though brain injury, brain cancer, drug and alcohol misuse and stroke are some of the reasons for epileptic seizures, the exact reason for convulsions is not known.
Some of the common symptoms which occur before convulsions include, visual loss, strange feeling, nausea, numbness in body parts, headache and racing thoughts.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Anticonvulsant drugs are in high demand due to the higher occurrence of epileptic seizures that are caused by the disturbance in the electrical activity in the brain. This involves small attacks that shake the brain. The complex treatment is getting eased through research and development in neurology. Higher modern-healthcare technology is adding new developments, such as advanced barbiturates and other antiepileptic drugs.
Increasing awareness about the anticonvulsants available in the market and the patent expiration of many blockbuster drugs are some of the major factors that are driving the global anticonvulsants market.
The generic medication for the treatment of epilepsy through anticonvulsants is a long process and can only be processed through specific treatments along with efficacious drugs made by different pharma giants. Although, generic medicines have not been that successful in terms of effectiveness.
The geriatric population and their screen addictions involve long hours of mobile and laptop usage, increasing the chances of epilepsy and convulsion conditions.
The common symptoms involve visual loss, strange feelings, nausea, headache, numbness in the body, and racing thoughts. Through these conditions, the convulsions are tracked. Companies make anticonvulsants according to specific conditions.
These factors are responsible for fueling the market for Anticovaculants.
Principal Consultant
The traditional practices and long and high-cost treatment has led to the slowdown of the anticonvulsants market. The side effects of anti-seizure medications with liver and skin conditions also limit the demand for anticonvulsants.
The major clinical indications that lead to seizure conditions are discussed as follows:
Diabetes
The high blood sugar levels that are common in diabetes can easily damage nerves throughout your body. The first symptom generally can be numbness and pain in the hands and feet, which is also known as diabetic neuropathy.
Shingles
People with conditions such as shingles are at risk of developing postherpetic neuralgia. This happens when the pain from shingles persists after the rash disappears.
Chemotherapy
Some chemotherapy drugs can damage nerves, causing pain and numbness that generally begins in the tips of your toes and fingers (neuropathy). This involves the condition of different epileptic conditions, fueling the demand for anticonvulsant drugs.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increasing awareness about the anticonvulsants available in the market, patent expiration of many blockbuster drugs are some of the major factors that are driving the global anticonvulsants market towards growth. There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the US by FDA. Moreover, three trends involving consumption of AEDs have become clinically important and must be considered by all who treat patients with epilepsy.
These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. While, high costs and unavailability of convenient dosage forms of both generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market.
Seizures are expected to result in physical, psychological and social repercussions. People with epilepsy could adhere rigorously to their medication regimes in order to prevent these deleterious outcomes. Treatment of epileptic seizures has led to the growth of anticonvulsants market. Barbiturates were the first antiepileptic drugs. These are more effective and tolerable than bromides.
Hydantoins are the first to be known as modern antiepileptic drugs. Succinimides are an old group of drug which are rarely prescribed nowadays. Consequently with these antiepileptic or antiseizure drugs, anticonvulsants market is growing immensely leaving a significant impact on the treatment of epileptic seizures.
The antiepileptic drug market is threatened by generic completion, which has been increasing dramatically in the face of patent expirations among several of the major branded antiepileptics. However, there have been cases where generic antiepileptic drugs have not been as efficacious as their branded counterparts have.
Region wise, the global anticonvulsants marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Currently, North America dominates the anticonvulsants market followed by Europe. Asia-Pacific is expected to emerge as a lucrative region, owing to factors such as increasing healthcare spending, improving healthcare infrastructure, and increasing demand for drugs. Given these factors, the market for anticonvulsants is likely to grow rapidly in Asia-Pacific region.
Some of the key players, contributing to global anticonvulsants drug market, are Johnson & Johnson (J&J), Novartis AG, UCB Group, GlaxoSmithKline plc, Pfizer Inc., Abbott Laboratories, Cephalon Inc. and Shire plc. Pfizer has been estimated to cover the largest market share in the antiepileptic market, accounting for close to one-third of total revenues of the market with it two leading brands.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Anticonvulsants market is segmented based on product type, application, end user and geography.
The market is likely to register a CAGR of 2.4% through 2032.
The market is currently valued at US$ 25.17 Bn in 2022.
The market is likely to grow to a valuation of US$ 31.91 Bn by 2032.
North America is likely to be a leading market during the forecast period.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Product Type 6.2. Application 6.3. End User 7. Global Market Analysis and Forecast, By Product Type 7.1. Barbiturates 7.2. Aldehydes 7.3. Benzodiazepines 7.4. Aromatic allylic alcohols 7.5. Carboxamides 7.6. Bromides 7.7. Carbamates 7.8. Sulfonamides 7.9. Fructose derivatives 7.10. Pyrrolidines 7.11. Triazines 7.12. Fatty acids 8. Global Market Analysis and Forecast, By Application 8.1. Epilepsy 8.2. Fibromyalgia 8.3. Migraine 8.4. Neuropathic pain 8.5. Bipolar disorder 8.6. Anxiety 8.7. Borderline personality disorder 9. Global Market Analysis and Forecast, By End User 9.1. Hospitals 9.2. Clinics 9.3. Ambulatory surgical clinics 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. Asia Pacific 10.6. Japan 10.7. Middle East & Africa 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 15. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 16. Japan Sales Analysis and Forecast, by Key Segments and Countries 17. Middle East & Africa Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Product Type, Application, and End User for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Johnson & Johnson (J&J) 20.2. Novartis AG 20.3. UCB Group 20.4. GlaxoSmithKline plc 20.5. Pfizer Inc. 20.6. Abbott Laboratories 20.7. Cephalon Inc. 20.8. Shire plc. 20.9. Pfizer
Explore Healthcare Insights
View Reports
Anticonvulsants Market
